AGIO - Agios Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
AGIO price evolution
AGIO
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $84.52 | $118.76 | $88.2 | $64.33 |
| Short term investments | $485.37 | $479.23 | $688.72 | $583.15 |
| Net receivables | $3.76 | $3.45 | $2.81 | $1.18 |
| Inventory | $23.94 | $23.07 | $19.08 | $17.27 |
| Total current assets | $632.13 | $663.63 | $833.84 | $704.35 |
| Long term investments | $75.4 | $116.3 | $29.43 | $224.9 |
| Property, plant & equipment | $61.48 | $65.72 | $69.79 | $73.95 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $140.94 | $186.08 | $103.28 | $302.91 |
| Total investments | $560.78 | $595.53 | $718.16 | $808.06 |
| Total assets | $773.06 | $849.71 | $937.12 | $1007.26 |
| Current liabilities | ||||
| Accounts payable | $10.04 | $11.15 | $9.78 | $13.27 |
| Deferred revenue | ||||
| Short long term debt | $15.86 | $15.41 | $15.01 | $14.66 |
| Total current liabilities | $62.64 | $51.69 | $67.95 | $58.42 |
| Long term debt | $48.76 | $52.94 | $56.99 | $60.83 |
| Total noncurrent liabilities | $49.92 | $54.1 | $58.14 | $61.99 |
| Total debt | $64.62 | $68.35 | $72 | $75.5 |
| Total liabilities | $112.55 | $105.79 | $126.1 | $120.42 |
| Shareholders' equity | ||||
| Retained earnings | -$1000.32 | -$904.2 | -$822.65 | -$726.71 |
| Other shareholder equity | -$1.04 | -$1.09 | -$0.44 | -$5.9 |
| Total shareholder equity | $660.51 | $743.92 | $811.02 | $886.84 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $88.2 | $139.26 | $203.13 | $127.44 |
| Short term investments | $688.72 | $643.86 | $816.89 | $445.49 |
| Net receivables | $2.81 | $2.21 | $4.38 | $25.4 |
| Inventory | $19.08 | $8.49 | $14.7 | |
| Total current assets | $833.84 | $832.77 | $1064.23 | $636.68 |
| Long term investments | $29.43 | $313.87 | $266.38 | $97.61 |
| Property, plant & equipment | $69.79 | $88.12 | $104.23 | $117.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $103.28 | $405.95 | $373.5 | $216.28 |
| Total investments | $718.16 | $957.73 | $1083.27 | $543.1 |
| Total assets | $937.12 | $1238.72 | $1437.74 | $852.95 |
| Current liabilities | ||||
| Accounts payable | $9.78 | $18.62 | $16.7 | $26.84 |
| Deferred revenue | ||||
| Short long term debt | $15.01 | $13.66 | $11.16 | $7.41 |
| Total current liabilities | $67.95 | $62.63 | $59.83 | $94.39 |
| Long term debt | $56.99 | $72 | $85.94 | $359.06 |
| Total noncurrent liabilities | $58.14 | $75.28 | $85.94 | $359.06 |
| Total debt | $72 | $85.66 | $97.09 | $366.47 |
| Total liabilities | $126.1 | $137.9 | $145.76 | $453.45 |
| Shareholders' equity | ||||
| Retained earnings | -$822.65 | -$470.56 | -$238.76 | -$1843.47 |
| Other shareholder equity | -$0.44 | -$12.54 | -$1.2 | $0.1 |
| Total shareholder equity | $811.02 | $1100.81 | $1291.97 | $399.5 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.62 | $8.19 | $7.1 | $7.4 |
| Cost of revenue | $1.5 | $0.63 | $0.59 | $0.63 |
| Gross Profit | $7.12 | $7.56 | $6.52 | $6.77 |
| Operating activities | ||||
| Research & development | $77.4 | $68.62 | $77.49 | $81.84 |
| Selling, general & administrative | $35.54 | $31.01 | $35.3 | $25.82 |
| Total operating expenses | $112.94 | $99.63 | $112.79 | $107.66 |
| Operating income | -$105.82 | -$92.07 | -$106.28 | -$100.9 |
| Income from continuing operations | ||||
| EBIT | -$96.12 | -$81.55 | -$95.94 | -$91.32 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$96.12 | -$81.55 | -$95.94 | -$91.32 |
| Income (for common shares) | -$96.12 | -$81.55 | -$95.94 | -$91.32 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $26.82 | $14.24 | $203.2 | |
| Cost of revenue | $2.88 | $1.7 | $2.81 | |
| Gross Profit | $23.94 | $12.54 | $200.39 | |
| Operating activities | ||||
| Research & development | $295.53 | $279.91 | $256.97 | $367.47 |
| Selling, general & administrative | $119.9 | $121.67 | $121.44 | $149.07 |
| Total operating expenses | $415.43 | $263.88 | $371.78 | $516.54 |
| Operating income | -$391.49 | -$251.34 | -$371.78 | -$316.15 |
| Income from continuing operations | ||||
| EBIT | -$352.09 | -$231.8 | $1604.71 | -$327.37 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$352.09 | -$231.8 | $1604.71 | -$327.37 |
| Income (for common shares) | -$352.09 | -$231.8 | $1604.71 | -$327.37 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$96.12 | -$81.55 | -$95.94 | -$91.32 |
| Operating activities | ||||
| Depreciation | $4.45 | $4.15 | $4.16 | $4.33 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.56 | $9.23 | $13.81 | $9.08 |
| Total cash flows from operations | -$72.59 | -$99.87 | -$72.49 | -$61.64 |
| Investing activities | ||||
| Capital expenditures | -$0.16 | -$0.1 | -$0.23 | $0.81 |
| Investments | $37.4 | $124.66 | $95.75 | $56.03 |
| Total cash flows from investing | $37.24 | $124.56 | $95.51 | $39.34 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.1 | $5.86 | $0.85 | $1.88 |
| Net borrowings | ||||
| Total cash flows from financing | $1.1 | $5.86 | $0.85 | $1.88 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$34.25 | $30.56 | $23.87 | -$20.42 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$352.09 | -$231.8 | $1604.71 | -$327.37 |
| Operating activities | ||||
| Depreciation | $17.34 | $18.56 | $18.78 | $18.97 |
| Business acquisitions & disposals | $131.78 | |||
| Stock-based compensation | $44.77 | $49.3 | $53.51 | $75.12 |
| Total cash flows from operations | -$296.06 | -$309.48 | -$314.09 | -$290.76 |
| Investing activities | ||||
| Capital expenditures | $0.33 | -$3.92 | -$5.74 | -$14.91 |
| Investments | $256.75 | $115.39 | -$548.42 | $90.66 |
| Total cash flows from investing | $239.57 | $243.26 | -$554.16 | $75.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.43 | $2.68 | -$765.19 | $11.32 |
| Net borrowings | -$0.33 | -$0.58 | $250.2 | |
| Total cash flows from financing | $5.43 | $4.7 | -$1531.54 | $261.52 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$51.05 | -$63.87 | $75.69 | $46.51 |
News
Fundamentals
| Market cap | $2.46B |
|---|---|
| Enterprise value | $2.44B |
| Shares outstanding | 56.88M |
| Revenue | $31.31M |
|---|---|
| EBITDA | -$347.85M |
| EBIT | -$364.93M |
| Net Income | -$364.93M |
| Revenue Q/Q | 28.35% |
| Revenue Y/Y | N/A |
| P/E ratio | -6.75 |
|---|---|
| EV/Sales | 77.99 |
| EV/EBITDA | -7.02 |
| EV/EBIT | -6.69 |
| P/S ratio | 78.63 |
| P/B ratio | 3.72 |
| Book/Share | 11.63 |
| Cash/Share | 1.49 |
| EPS | -$6.42 |
|---|---|
| ROA | -40.92% |
| ROE | -47.05% |
| Debt/Equity | 0.16 |
|---|---|
| Net debt/EBITDA | -0.08 |
| Current ratio | 10.09 |
| Quick ratio | 9.71 |